Colinz Laboratories open offer sees only six shares tendered at ₹54
- Only six equity shares were tendered in the open offer for Colinz Laboratories, valuing just ₹324 against a potential ₹3.54 crore.
- Acquirers Annjana Dugar, Likhitta Dugar, and Antariksh Dugar offered ₹54 per share to buy up to 26% of the voting share capital.
- The open offer was triggered by a pending Share Purchase Agreement for 8,70,500 shares (34.56%) which remains unconsummated.
- Public shareholding stands at 34.39% post-offer, subject to downward revision upon reclassification of promoter-held shares.

*this image is generated using AI for illustrative purposes only.
The open offer for Colinz Laboratories attracted negligible interest from public shareholders, with only six equity shares tendered during the offer period that ran from August 7 to August 20, 2026.
Acquirers Annjana Dugar, Likhitta Dugar, and Antariksh Dugar, along with Person Acting in Concert (PAC) Padam Dugar, proposed to acquire up to 6,54,966 fully paid-up equity shares at a price of ₹54 per share. The maximum aggregate consideration for the offer was valued at ₹3,53,68,164, representing 26% of the company’s voting share capital.
Despite the significant size of the mandatory open offer under SEBI (SAST) Regulations, 2011, actual acceptances were minimal. The acquirers accepted the six shares tendered in dematerialized form, resulting in an actual acquisition value of just ₹324.
What the Numbers Show
The divergence between the proposed offer size and actual acceptances highlights a lack of exit interest from existing public shareholders at the offered price. While the acquirers planned to acquire 26% of the voting share capital through the open offer assuming full acceptance, the actual acquisition via this route was negligible. The post-offer shareholding pattern reflects this reality, with the public holding remaining largely unchanged at 34.39% post-offer compared to 49.40% pre-offer, although this figure includes reclassification adjustments.
Shareholding Structure Changes
The acquirers held 3,78,000 shares (15.01%) prior to the public announcement. The open offer was triggered by their agreement to acquire an additional 8,70,500 shares (34.56%) through a Share Purchase Agreement dated June 18, 2026. As of the post-offer advertisement dated September 3, 2026, these transactions had not yet been consummated.
| Metric | Proposed (Full Acceptance) | Actuals |
|---|---|---|
| Shares Tendered | 6,54,966 | 6 |
| Offer Price | ₹54 | ₹54 |
| Aggregate Value | ₹3,53,68,164 | ₹324 |
| Post-Offer Acquirer Holding | 75.57% | 49.57% |
Upon consummation of the Share Purchase Agreement, the 3,78,000 shares currently classified under the public category will be reclassified to the Promoter/Promoter Group category. This reclassification will further adjust the public holding percentage downwards from the reported 34.39%.
Saffron Capital Advisors Private Limited served as the manager to the open offer, while Bigshare Services Private Limited acted as the registrar. Payment for the accepted shares was made on August 28, 2026.
Historical Stock Returns for Colinz Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.01% | +4.15% | -13.07% | +72.74% | +68.41% | +320.29% |
How might the negligible public participation in the open offer impact Colinz Laboratories' future liquidity and trading volume on the stock exchange?
What are the strategic implications for the Dugar family's control over Colinz Laboratories once the pending Share Purchase Agreement is consummated?
Could the low acceptance rate signal underlying concerns among public shareholders regarding the company's valuation or future growth prospects at the ₹54 price point?

































